Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

A review examines how ubiquitin markings influence protein buildup in ALS

Original source

Ubiquitin signatures on aggregating proteins in neurodegeneration.Essays Biochem · 22 December 2025 (opens in a new tab)

Compass summarised this from the study's abstract.

Study details

Study type
Review
Studied in
Human, Animal

Related topics

A review examines how ubiquitin modifications affect the clearance, aggregation and spread of misfolded proteins linked to neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). It discusses proteins such as TAR DNA-binding protein 43 and superoxide dismutase 1, as well as enzymes that regulate ubiquitin pathways.

Why this matters

The review may help researchers understand how abnormal proteins are handled in ALS and identify possible targets for future treatments. It does not show that any treatment works, and it does not change current care.

Limitations and context

This is a review article, not a clinical trial or a new treatment study. The source does not provide patient results or establish that targeting these pathways benefits people with ALS. Any therapies discussed remain potential approaches unless tested in clinical studies.

Summarised by Compass 13 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Bibliographic data from PubMed is courtesy of the U.S. National Library of Medicine. Compass does not reproduce source abstracts and may not reflect the most current record.

Relevant to you?